publication venue for
- Exploring the predictive validity of personality disorder criteria.. 14:309-320. 2023
- Criterion A: Level of personality functioning in the alternative DSM-5 model for personality disorders.. 13:305-315. 2022
- Latent variable modeling of item-based factor scales: Comment on Triarchic or septarchic?-Uncovering the Triarchic Psychopathy Measure's (TriPM) Structure, by Roy et al.. 12:16-23. 2021
- An investigation of the influence of case and clinician gender in clinical decision-making.. 10:286-290. 2019
- Initial development of pathological personality trait domain measures using the Personality Assessment Inventory (PAI).. 9:564-573. 2018
- Personality and life events in a personality disorder sample.. 8:376-382. 2017
- Gender-related differential item functioning in DSM-IV/DSM-5-III (alternative model) diagnostic criteria for borderline personality disorder.. 8:87-93. 2017
- Narcissistic personality disorder in DSM-5.. 5:422-427. 2014
- The ironic fate of the personality disorders in DSM-5.. 4:342-349. 2013
- When is it time to move on? Rejoinder for "the ironic fate of the personality disorders in DSM-5".. 4:354-354. 2013
- No sympathy for the devil: attributing psychopathic traits to capital murderers also predicts support for executing them.. 4:175-181. 2013
- Is it the inventory, the meta-analysis, or the construct? Reply to the comments on Marcus, Fulton, and Edens.. 4:89-90. 2013
- The two-factor model of psychopathic personality: evidence from the psychopathic personality inventory.. 4:67-76. 2013
- The role of fearless dominance in psychopathy: confusions, controversies, and clarifications.. 3:327-340. 2012
- The two-factor model of psychopathic personality: Evidence from the Psychopathic Personality Inventory (vol 3, pg 140, 2012). 3:195-195. 2012
- Proposed changes in personality and personality disorder assessment and diagnosis for DSM-5 Part I: Description and rationale.. 2:4-22. 2011
- Proposed changes in personality and personality disorder assessment and diagnosis for DSM-5 Part II: Clinical application.. 2:23-40. 2011